Drug Trial Radar · NCT07504263
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Dec 1, 2027
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- Recurv Pharma IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
Conditions
- Advanced Malignancies
- Oncology
- Colorectal Cancer
- Pancreatic Cancer
- Cancer
Interventions
RP-001Drug
A new class of Taxane.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To characterize the safety and tolerability of RP-001 administered as monotherapy.Time frame: 1 month
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.